Corticotropin-releasing hormone (CRH), the principal regulator of the hypothalamic-pituitary-adrenal axis, is also secreted in peripheral inflammatory sites, where it acts as a local proinflammatory agent. Arthritis-susceptible LEW/N rats have profoundly deficient hypothalamic CRH responses to inflammatory stimuli and other stressors. Arthritis-resistant F344/N rats, on the other hand, have a robust increase in hypothalamic CRH in response to the same stimuli. Contrasting with these hypothalamic CRH responses, we now show that CRH expression is markedly increased in the joints and surrounding tissues of LEW/N rats with streptococcal cell wall-and adjuvant-induced arthritis, whereas it is not increased in similarly treated F344/N rats and is only transiently increased in congenitally athymic nude LEW.rnu/rnu rats. Glucocorticoid treatment suppressed, but did not eliminate, CRH immunoreactivity in the joints of LEW/N rats. CRH mRNA was present in inflamed synovia, as well as in spinal cord, and inflamed synovia also expressed specific CRH-binding sites. We compared CRH expression in inflamed joints with another well-characterized proinflammatory neuropeptide, substance P (SP), and found that SP immunoreactivity paralleled that of CRH. In summary, although LEW/N rats have deficient hypothalamic CRH responses to inflammatory stimuli compared with F344/N rats, they express relatively high levels of CRH at the site of inflammation. Analogous to SP, CRH may be delivered to the inflammatory site by peripheral nerves and/or synthesized at the inflammatory site. These data provide further support for the concept that CRH not only triggers the pituitary-adrenal antiinflammatory cascade, but also functions as an antithetically active local mediator of acute and chronic inflammatory arthritis. These data also illustrate the complex interrelationships of the nervous, endocrine, immune, and inflammatory systems. (J.
Introduction
The nervous, endocrine, immune, and inflammatory systems are intimately intertwined through overlapping regulatory me-diator production and receptor expression. The hypothalamicpituitary-adrenal (HPA)' axis exerts significant antiinflammatory effects, predominantly through glucocorticoid suppression of inflammatory cell recruitment, production and action of proinflammatory cytokines, and other mediators of inflammation. Corticotropin-releasing hormone (CRH), a 41 -amino acid hypothalamic neuropeptide, is the major stimulus to pituitary production ofACTH, which in turn stimulates the production of glucocorticoids by the adrenal cortex. Our group recently investigated HPA axis responses to multiple inflammatory and noninflammatory stimuli in arthritis-susceptible Lewis (LEW/N) and relatively arthritis-resistant Fischer (F344/N) rat strains. LEW/N rats have a deficient hypothalamic CRH response to virtually all these stimuli, whereas F344/N rats display robust increases in hypothalamic CRH, with resultant differences in levels of plasma ACTH and corticosterone (1) (2) (3) (4) (5) . Our group postulated that these differences in HPA axis responses play a role in the differing susceptibility of LEW/N and F344/N rats to experimentally induced inflammatory arthritis and other experimental autoimmune diseases (6) (7) (8) (9) (10) (11) .
Neuropeptides derived from peripheral nerves also play important roles in the expression of inflammatory reactions ( 12) . For example, substance P (SP), which is primarily derived from sensory afferent unmyelinated c fibers, significantly augments the local inflammatory response (13) (14) (15) (16) . Many other neuropeptides are present in sensory afferent unmyelinated c and small myelinated A-6 fibers, but their contribution to inflammation remains less well defined. Capsaicin (8-methyl-Nvanillyl-6-nonenamide) causes selective depletion ofneuropeptides or destruction of primary sensory neurons and has been shown to markedly decrease inflammation ( 17, 18) . Immunoreactive CRH is present in the spinal cord and is also depleted by capsaicin treatment ( 19). Levine and colleagues ( 18, 20, 21 ) have demonstrated that both sensory afferent and sympathetic efferent nerve fibers contribute to the severity of inflammatory arthritis. Because CRH is localized to the dorsal sensory and sympathetic interomediolateral columns ofthe spinal cord ( 19, 22) , as well as to the dorsal root and sympathetic ganglia (23, 24) , it is reasonable to speculate that neuron-derived CRH, along with SP and other neuropeptides, contributes to the inflammatory process.
A growing body of data now support direct involvement of CRH in inflammation. CRH receptors are present on resident macrophages of mouse spleen (25) and human peripheral blood lymphocytes and monocytes (26) . Also, immunoreactive CRH (iCRH) and CRH mRNA are expressed in human peripheral blood leukocytes (27) . CRH has direct in vitro effects on cells of the immune system, including stimulation of lymphocyte proliferation and expression of the interleukin-2 receptor (28, 29) , stimulation of leukocyte secretion of interleukin-1 and interleukin-2 (30, 31) , and induction of leukocyte-derived ACTH and f3-endorphin (32) . Lastly, our groups recently provided evidence that CRH is active locally in an in vivo rat model ofacute inflammation. Carrageenin, a seaweedderived polysaccharide, produces a chemical inflammatory response when subcutaneously injected in rats. Immunoneutralization of CRH reduces both the volume and cellularity of the exudate in male Harlan-Sprague-Dawley rats, indicating that CRH has a predominantly proinflammatory effect. In this model, the antiinflammatory effect of anti-CRH antibody is equivalent to the antiinflammatory effect ofanti-tumor necrosis factor-a antibody (33) .
In the current study, we evaluate the hypothesis that CRH is locally expressed in inflammatory arthritis in the rat. We studied CRH expression in the joints of LEW/N, F344/N, and congenitally athymic nude LEW.rnu/rnu inbred rat strains after injection of streptococcal cell walls (SCW) or mycobacterial adjuvant. Because LEW/N rats have deficient hypothalamic CRH production, we were particularly interested in their ability to increase their peripheral iCRH in response to inflammation. Inflamed synovia were examined for the presence of CRH receptor-binding activity to assure the potential for local biological activity. Additionally, we examined synovial tissues, spleens, and spinal cords for CRH mRNA to identify the source of peripherally localized iCRH. To determine whether CRH was expressed similarly to other neuropeptides in the inflamed joint, we compared CRH expression with SP, a wellcharacterized proinflammatory neuropeptide, by immunohistochemistry and mRNA analysis. Because glucocorticoids downregulate hypothalamic CRH expression, we evaluated the effect of glucocorticoids on local expression of iCRH. Induction ofexperimental polyarthritis. SCW peptidoglycan-polysaccharide fragments were prepared as previously described (34) . A sterile aqueous suspension of sonicated SCW in PBS, pH 7.4, was administered by intraperitoneal injection at a dose equivalent to 20 ,ug of rhamnose/g body weight. This dose has been previously determined to result, with 100% incidence, in acute and chronic polyarthritis in 6-wkold female LEW/N rats and acute, but not chronic, polyarthritis in athymic LEW.rnu/rnu rats. 6-wk-old female F344/N rats were also injected. Rats were killed at day 0 (uninjected) or at days 3 or 28 after injection.
Methods
Adjuvant arthritis was induced in arthritis-susceptible LEW/N rats by intradermal injection of200 ,l ofpulverized Mycobacterium butyricum (Difco Laboratories, Detroit, MI) at a concentration of 10 mg/ml in heavy paraffin oil at eight separate sites, four on each side, in the periscapular region with a 25-gauge needle, while the animals were under light anesthesia by CO2 narcosis. Athymic LEW.rnu/rnu and relatively arthritis-resistant F344/N rats that usually do not develop clinically apparent arthritis were also injected as described. Animals were killed at day 0 (uninjected) or at days 4, 10, or 18 after injection. Hindfoot specimens were collected in 10% Formalin when the animals were killed, and then were decalcified in EDTA, embedded in paraffin, and sectioned at a thickness of 6 Mm onto gelatin-coated microscope slides.
Dexamethasone treatment ofSCW-injected LEW/N rats. A group of LEW/N rats injected with SCW was treated with glucocorticoids beginning on the day ofinjection (day 0). These animals received twice daily intraperitoneal injections of 1 ml PBS alone or PBS plus dexamethasone 0.005 or 0.05 gg/g body weight. Animals were killed at day 3 after SCW injection. Hindfoot specimens were processed as above.
Immunohistochemistry. For each tissue specimen, the extent and intensity of staining with CRH, SP, or control antibodies were graded on a scale of 0 to 4+ by a blinded observer on two separate occasions using coded slides. The observer assessed all tissues on each slide with particular attention to the histologic structures stained. A grade of4+ implies that staining ofa tissue was maximally intense throughout the specimen, whereas 0 implies that staining was absent throughout the specimen. This methodology has been used extensively in earlier studies (36) (37) (38) .
RNA preparation and analysis. Ankle synovia, spinal cords, and spleens were dissected from arthritic LEW/N rats on day 18 after adjuvant injection. Spinal cords and spleens were obtained from uninjected LEW/N rats, but we were unable to collect sufficient ankle synovia for RNA preparation from nonarthritic rats. Tissues for RNA extraction were minced, placed immediately into guanidine isothiocyanate buffer (4 M guanidine isothiocyanate, 25 mM sodium citrate, 0.05% sodium lauryl sarcosine, and 0.1 M #-mercaptoethanol, pH 7.0) on ice, homogenized, and then pelleted by centrifugation through a cesium chloride gradient (39 RNAse inhibitor (Perkin-Elmer Cetus Instruments), and 400 U M-MLV reverse transcriptase (Bethesda Research Laboratories, Gaithersburg, MD). The reaction mix was incubated at 370C for 30 min, diluted to 500 ,ul, and heated to 950C for 10 min. All PCR reactions were performed in a 50-,il reaction volume containing 5 Ml ofthe cDNA mix in 50 mM KC1, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl2, 50MM each ofdATP, dCTP, dGTP, and dTTP, 1 ng/,l each ofsense and antisense primers, and 5 U of Taq polymerase (Perkin-Elmer Cetus Instruments). Some reactions contained 5 Mul of a-[32P]dCTP 3,000 Ci/ mmol (New England Nuclear-Dupont, Boston, MA). The primers used were, for rat CRH, sense 5'-CTC AGA GCC CAA GTA CGT TGA-3' and antisense 5'-TGC TCC GGT TGC AAG AAA TTC-3'; for rat SP (preprotachykinin), sense 5'-AGA GGA AAT CGG TGC CAA CG-3' and antisense 5'-TTC GTA GTT CTG CAT TGC GC-3'; and for rat f-actin, sense 5'-ACC ACA GCT GAG AGG GAA ATC G-3' and antisense 5'-AGA GGT CTT TAC GGA TGT CAA CG-3'. All primer pairs amplified a fragment that crossed an intron, thereby distinguishing between cDNA and contaminating genomic DNA by the size of the expected fragment after amplification. The primers for SP (preprotachykinin) were designed to distinguish between the a, fl, and ry forms of preprotachykinin mRNA, all of which can give rise to SP by posttranslational processing (40) . The (41 ) . The membrane was hybridized in 50% formamide at 42°C for 24 h with 1.5 X 107 cpm of the cRNA probe, and then washed twice for 20 min at 55°C in 0.1% sodium dodecyl sulfate, 15 mM NaCl, and 1.5 M sodium citrate. The membrane was exposed to Kodak XAR film for 1 to 12 h at room temperature.
CRH-binding assay. The affinity and concentration of CRH-binding sites were determined from competitive displacement binding experiments in which rat synovial tissue homogenates and '251I-Tyr-ovine CRH (1251I-oCRH) (New England Nuclear, Boston, MA) were incubated with increasing concentrations of rat/human CRH (Peninsula Laboratories, Inc., Belmont, CA). Synovial tissues were dissected from the ankle joints of LEW/N rats on day 18 after adjuvant injection, frozen on dry ice, and stored at -80°until assayed. At the time ofassay the frozen synovial tissues were weighed and then homogenized using a polytron (Brinkman Instruments, Inc., Westbury, NY) at a setting of 5 for 30 s in 20 vol of ice-cold homogenization buffer (50 mM Tris-HCl, 10 mM MgCl2, and 2 mM EGTA, pH 7.2) and centrifuged at 38,000 g for 10 min. The pellets were suspended to a final concentration of 40 mg tissue wet weight/ml in homogenization buffer. 100 Ml ofthe membrane preparation was added to a 1.5-ml polypropylene microtube containing 100 ,l of a rat/human CRH solution (12 concentrations ranging from 0 to 1 MM) and 100 Ml of '25I-oCRH (0.2 nM final concentration) in incubation buffer (50 mM Tris-HCl, 10 mM MgCl2, 2 mM EGTA, 0.15% bovine serum albumin, 100 kallikrein inhibitor U/ml aprotinin, 0.15 mM bacitracin, pH 7.2). The reaction was allowed to proceed for 2 h at room temperature. The tissue was separated from the incubation medium by centrifugation in a microfuge for 8 min at 12,000 g. The supernatant was aspirated, the pellets washed gently with 1 ml of PBS containing 0.01% Triton X-100, and the radioactivity of the pellet was measured in a y counter. It has been previously determined that protease and enzyme inhibitors used to prevent CRH receptor degradation do not themselves bind CRH (42) . The final protein concentration was determined using the BCA protein assay (Pierce Chemical Co., Rockford, IL). The 125I-oCRH-binding data were analyzed by the Macintosh-based nonlinear least-squares curve-fitting computer program LIGAND (43) .
Results
CRH immunostaining in SCW-injected rats. Euthymic LEW/ N and congenitally athymic LEW.rnu/rnu, but not relatively arthritis-resistant F344/N, rats develop erythema and swelling of peripheral joints within 24 h after injection of SCW (6, 34, 44) . The acute phase of SCW-induced polyarthritis increases to a maximum at 3 d, and then gradually subsides. Euthymic LEW/N, but not athymic LEW.mu/rnu or F344/N, rats go on to develop T cell-dependent chronic polyarthritis that reaches maximum severity by 28 d after SCW injection. Histologically, the acute polyarthritis is characterized by edema, deposition of fibrin in the synovia and joint space, and infiltration by granulocytes and macrophages. In the chronic phase of SCW-induced arthritis, there is marked synovial connective tissue cell (/) Except for low grade staining in the bone marrow, hindfoot specimens from uninjected rats showed little CRH immunoreactivity in any rat strain (Table I and Fig. 1, A, D, and G) . However, by day 3 after SCW injection, CRH immunostaining increased markedly in euthymic LEW/N and athymic LEW.rnu/rnu rats, but not F344/N rats (Table I) . iCRH was present in many different sites, including the epidermis, synou-I vium (lining cell layer, vascular endothelium, mononuclear Cl') inflammatory cells, and stromal fibroblast-like cells), cartilage chondrocytes, subchondral bone, and bone marrow. At day 28 -after injection of SCW, euthymic LEW/N rats expressed high levels of iCRH (Table I and Fig. 1 , B, E, and H) in joints and surrounding tissues, whereas athymic LEW.rnu/rnu and F344/ N rats were not different from control animals. Immunostaining with nonspecific rabbit IgG (data not shown) or anti-CRH antibody depleted by adsorption on CRH-Sepharose (Fig. 1 , C, F, and I) was uniformly negative.
Effects of dexamethasone on CRH immunostaining in acute SCW-induced arthritis. We treated LEW/N rats with twice daily injections of dexamethasone or PBS beginning on the day of SCW injection to assess the effect of glucocorticoids on iCRH expression in acute SCW-induced arthritis. We observed a dose-dependent decrease in the extent and intensity of CRH immunoreactivity after dexamethasone treatment (Table II). 10 Hindfoot specimens from LEW/N, LEW.rnu/rnu, and F344/N rats on day 0 (uninjected), and on days 4, 10, and 18 after adjuvant injection were evaluated for CRH immunoreac-_ g --; tivity (Table III) . LEW/N rats showed upregulated iCRH expression beginning on day 4 of mononuclear inflammatory cells into the joints and surrounding tissues. Athymic LEW.rnu/rnu rats also showed increased CRH immunoreactivity at day 4 that was not sustained by day 10 after adjuvant injection. Relatively adjuvant arthritis-resistant F344/N rats did not increase CRH immunostaining after injection with adjuvant. Expression ofCRH mRNA in adjuvant-injected rats. CRH mRNA is known to be expressed in many regions ofthe brain, including hypothalamus, cerebral cortex, striatum, hippocampus, midbrain, and brainstem. CRH mRNA has also been detected in spinal cord, pituitary, adrenal, and testis (46) . We used PCR to evaluate CRH mRNA expression during adjuvant-induced arthritis (Fig. 2 A) . Amplification of cDNA with the primers used in this study predicted a fragment of 311 tion, which is the time of maximally severe arthritis, fragments of the predicted size were detected in synovia and spleens, as well as spinal cords.
CRH equilibrium binding characteristics ofrat adjuvant arthritic synovia. Equilibrium binding of 1251I-oCRH was measured in homogenates of rat synovial tissues collected on day 18 after adjuvant injection using assay conditions identical to those described for membrane preparations from mouse spleens (47 (Fig. 3) . Simultaneous analysis of these Scatchard plot data using the nonlinear curve-fitting program LIGAND suggested that the data best fit a two-site rather than a single-site model, although this difference did not reach statistical significance (P = 0.076 Immunostaining ofSP in SCW-and adjuvant-injected rats.
The extent and intensity of immunostaining for SP paralleled the immunostaining for CRH in LEW/N rats, both in SCW-injected (Fig. 4) and adjuvant-injected rats (data not shown).
The tissue localization of SP was also very similar to that of iCRH.
Expression of SP (preprotachykinin) mRNA in adjuvantinjected rats. SP is a member ofthe tachykinin family ofneuropeptides that is generated by posttranslational processing of preprotachykinin (PPT) mRNA. Three different alternatively spliced mRNAs are generated from a single gene. a-PPT mRNA is processed only to SP, whereas,B-PPT mRNA can be processed to SP, neurokinin A, or neurokinin K; and -y-PPT can be a precursor for SP, neurokinin A, or neuropeptide y (40) . Fragments of the expected sizes for the a, ,B, and -y forms of PPT mRNA were easily detectable in control spinal cord and in day 18 Corticotropin-releasing Hormone Expression in Inflammatory Arthritis 2561 tectable in synovium from adjuvant-arthritic rats (Fig. 2 B) . The relative abundance ofthe PPT mRNA forms in the spinal cord was y > » > a, consistent with previous reports for rat nervous tissues (40) . We showed a similar pattern of mRNA forms in synovial tissue. In spleen there were differences in the relative abundance of the 13 and y forms in control and adjuvant-arthritic rats, the significance of which is unknown, and the a form was not detected (Fig. 2 B) .
Discussion
Immunoreactive CRH expression was markedly increased in the joints and surrounding tissues of rats with acute and chronic SCW-induced and adjuvant-induced arthritis. The extent and intensity of CRH immunoreactivity generally paralleled the severity of the inflammatory response. There were striking strain differences in the local expression of iCRH. Arthritis-susceptible euthymic LEW/N rats exhibited high levels of iCRH expression in both acute and chronic SCW-induced and adjuvant-induced arthritis, whereas F344/N rats had no such increases in response to either SCW or adjuvant. Congenitally athymic LEW.rnu/rnu rats developed increased iCRH on day 3 after SCW injection that returned to baseline levels by day 28, indicating that T cells are required for sustained high level CRH expression in the joints. In contrast to local iCRH, we have previously shown that iCRH production in the hypothalamus is blunted in LEW/N rats in response to numerous stimuli, including SCW, whereas F344/N rats show marked increases in hypothalamic iCRH production in response to the same stimuli (1) (2) (3) (4) (5) . To summarize, arthritis-susceptible LEW/ N rats have a deficient hypothalamic CRH response to inflammatory stimuli but express high levels of iCRH in inflammatory sites, whereas F344/N rats exhibit the opposite CRH responses. Hypothalamic CRH influences glucocorticoid levels and, thus, indirectly exerts antiinflammatory and immunosuppressive effects on that basis. However, the available data indicate that peripheral CRH is proinflammatory (33) . These observations support our conclusion that CRH expression is differentially regulated in the central nervous system and periphery, is subject to genetically determined variation, and exhibits functionally antithetical effects on the inflammatory process.
Glucocorticoids are known to exert negative feedback on hypothalamic CRH-containing neurons, resulting in downregulation of CRH mRNA and decreased secretion of CRH (41, 48) . In this study, we investigated the effect ofdexamethasone on local iCRH production in acute SCW-induced arthritis in LEW/N rats and found a dose-dependent decrease of iCRH. However, the inhibition of mononuclear cell infiltration was more pronounced than the inhibition of iCRH expression. After (27) . We also detected a CRH-specific fragment, by PCR amplification of reverse-transcribed RNA from the synovia and spleens from adjuvant arthritic LEW/N rats. The specific cells that synthesize CRH at the inflammatory site are not yet certain, but our results combined with previous observations suggest that infiltrating mononuclear cells may be one source ofCRH synthesis within the inflammatory site. CRH mRNA was also found in the spinal cord of control and adjuvant-arthritic LEW/N rats. These data, along with the incomplete inhibition of iCRH expression by dexamethasone and the presence ofiCRH on day 4 after adjuvant injection before the influx of mononuclear inflammatory cells, are consistent with the hypothesis that, analogous to SP, iCRH is also synthesized and released by the peripheral nervous system.
In the present study, we have identified specific CRH-bind- Other peripheral nervous system-derived neuropeptides are thought to influence the inflammatory process (12) . SP, neurokinin A, somatostatin, vasoactive intestinal peptide, cholecystokinin, and calcitonin gene-related peptide are peptide products of capsaicin-sensitive sensory afferent fibers. CRH is also depleted in the rat spinal cord in response to capsaicin ( 19). Much attention has been focused on SP, which can evoke many signs of acute inflammation and inflammatory arthritis, including vasodilation, increased vascular permeability, T lymphocyte proliferation, mast cell degranulation, macrophage activation, granulocyte activation and chemotaxis, fibroblast proliferation, and synoviocyte secretion ofprostaglandin E2 and collagenase ( 14, 18, (49) (50) (51) (52) (53) (54) . SP-containing nerve terminals have been demonstrated in normal rat synovium but are not detectable in the superficial lining and sublining zones of synovium from adjuvant-arthritic rats (55) . This finding could be explained by depletion of peptidergic nerve terminals of their neuropeptide content. Alternatively, hyperplastic synovium of arthritic joints could outgrow its nerve supply (55) . Direct injection of SP significantly augments radiographically assessed joint destruction in adjuvant-induced arthritis ( 18, 56) , and inflammation in the rat knee joint induced by carrageenin can be inhibited by SP antagonists ( 16) . We observed immunoreactive SP in the synovia and surrounding tissues of LEW/N rats with arthritis in a distribution that paralleled to iCRH. SP (preprotachykinin) mRNA was easily detectable in 2562 spinal cords, but also in synovial tissues from adjuvant arthritic rats, suggesting that SP is also synthesized locally.
In addition to the peripheral sensory afferent system, the sympathetic efferent system also contributes to the inflammatory process in adjuvant-induced arthritis (57) . Corderre and colleagues (58) showed that chemical sympathectomy with 6-hydroxydopamine markedly reduces the radiologically assessed joint destruction of adjuvant-induced arthritis. Therefore, sympathetic system-derived or -dependent proinflammatory substances may play a role in tissue destruction.
Immunoreactive CRH is present in the interomediolateral sympathetic column, particularly in the thoracic and lumbar segments of the spinal cord (22) , as well as in the ganglia of the sympathetic chain (23, 24) , and our work suggests that locally secreted CRH may play a role in the pathological process of adjuvant-induced arthritis. Further studies are needed to evaluate the relative contributions of CRH delivered to the joints by the peripheral nervous system and CRH that is synthesized locally in joint tissues.
In summary, these data provide support for our view that CRH is not only a major regulator of the HPA axis but also directly involved in the inflammatory process. There is markedly increased iCRH in carrageenin-induced acutely inflamed tissue (33) , acute and chronic SCW-induced arthritis and adjuvant-induced arthritis. Specific CRH-binding activity is present in inflamed synovial tissue from adjuvant-arthritic rats. Additionally, CRH mRNA is synthesized in synovia from arthritic rats, but CRH may also be delivered to the joint by peripheral nerves. CRH appears to be a multifunctional neuropeptide regulator of inflammation, whose expression and effects are site specific.
